MAY 13, 2020 8:18 AM PDT

FDA Fast Tracks Vaccine for COVID-19

WRITTEN BY: Annie Lennon

Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental COVID-19 vaccine for a Phase II trial. 

The vaccine, known as mRNA-1273, was developed by both Moderna and the National Institutes of Health. It was the first candidate to enter a Phase I human trial in March. Although the results of this trial remain unpublished, the FDA granted them federal approval to continue their research via Phase II trial soon. Meanwhile, the company hopes to begin phase III trials, the final trialing phase, early this summer. 

One of the reasons for the vaccine’s swift approval is that it operates via a system used to make other vaccines that has shown to be both effective and without huge risk to patients’ health. Rather than using an inactive form of COVID-19, this method instead introduces patients to synthetic RNA molecules in the hope that their body will recognize them as the virus and produce antibodies that may also fight against the real thing. 

In the vaccine’s Phase II trial, the researchers aim to assess the safety, reactogenicity and immunogenicity of two vaccinations given 28 days apart. They hope to recruit 600 healthy volunteers aged 18 and over, and will then follow each of them for 12 months after the second vaccination. 

Should the vaccine pass the Phase II trial, Moderna anticipates working closely with the US government to decide where its first doses will be delivered. To this end, the company has already begun scaling up its manufacturing capacity to rapidly distribute the vaccine once available. 

Optimistic, the company’s CEO Stephane Bancel nevertheless said that even if approved, supply of the vaccine will remain constrained for some time. Due to the number of cases of the virus globally, he added that soon, there will likely be more than one vaccine in circulation to fight the virus. 

 

Sources: CNBC, LabRoots, Clinical Trials Arena

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 21, 2022
Cancer
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
JUL 21, 2022
Can Microrobots Deliver Chemotherapy Directly to a Tumor?
Microrobotics, also called microbotics, is a field of study focusing on miniature robotics capable of carrying tiny comp ...
JUL 23, 2022
Drug Discovery & Development
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
JUL 23, 2022
Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19
An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with seve ...
JUL 23, 2022
Drug Discovery & Development
No Evidence for Depression and Serotonin Activity Link
JUL 23, 2022
No Evidence for Depression and Serotonin Activity Link
A new review study found that there is no clear evidence that serotonin levels or serotonin activity are responsible for ...
AUG 12, 2022
Technology
Bioengineered Cornea Helps Restore Sight for the Visually Impaired
AUG 12, 2022
Bioengineered Cornea Helps Restore Sight for the Visually Impaired
Corneal disease refers to a range of conditions that can cause significant damage to the cornea, the clear tissue layer ...
AUG 19, 2022
Neuroscience
Anterior Cingulate Cortex Plays a Key Role in Managing Additional Learning Tasks
AUG 19, 2022
Anterior Cingulate Cortex Plays a Key Role in Managing Additional Learning Tasks
A study published in Nature Communications reports that a key function of the anterior cingulate cortex (ACC) is to help ...
SEP 04, 2022
Drug Discovery & Development
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
SEP 04, 2022
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
Deep brain stimulation (DBS) may help control symptoms of binge-eating disorder and induce weight loss. The correspondin ...
Loading Comments...